Summary
Mean steady-state plasma concentrations of alprenolol were studied in relationship to the degree of beta-blockade, in sixteen patients receiving 600 mg daily in divided doses. Steady-state alprenolol concentrations were determined from the area under the plasma concentration-time curve during one eight-hour dosage interval after treatment for six weeks. Beta-blockade during alprenolol treatment was assessed from the chronotropic response to intravenous isoprenaline compared to the response after six weeks of placebo therapy. Although there was interindividual variability in the mean steady-state alprenolol concentration (range 11 — 141 ng/ml), and in the degree of beta-blockade (7-fold), the correlation between the two variables was highly significant (r=0.80, p<0.001). The prescribed dose of alprenolol (mg/kg) was not significantly correlated with the plasma level of alprenolol or the β-blockade. The chronotropic effects of isoprenaline during placebo and alprenolol were significantly interrelated (r=0.79, p<0.001).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Åblad, B., Johnsson, G., Norrby, A., Sölvell, L.: Potency and time effect relationship in man of propranolol and H 56/28-comparative studies after oral administration. Acta pharmacol. (Kbh.)25 (Suppl. 2), 85 - 94 (1967)
Åblad, B., Ervik, M., Hallgren, J., Johnsson, G., Sölvell, L.: Pharmacological effects and serum levels of orally administered alprenolol in man. Europ. J. clin. Pharmacol.5, 44 - 52 (1972)
Åblad, B., Borg, K.O., Johnsson, G., Regårdh, C.G., Sölvell, L.: Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxyalprenolol in man. Life Sci.14, 693 - 704 (1974)
von Bahr, C., Alván, G., Lind, M., Mellström, B., Sjöqvist, F.: “First-pass” effect and dose dependent availability as factors contributing to interindividual differences in equilibrium concentrations of alprenolol in man. Abstract. Int. Congress of Pharmacy, Stockholm 1974
Bodén, N.-O.: Identification of the major urinary metabolite of alprenolol in man, dog and rat. Life Sci.14, 685 - 692 (1974)
Collste, P., Haglund, K., Frisk-Holmberg, M., Orme, M.L.E., Rawlins, M.D., Östman, J.: Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. II. Relationship to its effect on blood pressure and plasma renin activity. Europ. J. clin. Pharmacol.10, 89 - 95 (1976)
Coltart, D.J., Shand, D.G.: Plasma propranolol levels in the quantitative assessment of β-adrenergic blockade in man. Br. med. J.1970 III, 731 - 734
Conolly, M.E., Davies, D.S., Dollery, C.T., George, C.F.: Resistance to β-adrenoceptor stimulants (a possible explanation for the rise in asthma deaths). Brit. J. Pharmacol.43, 389 - 402 (1971)
Ervik, M.: Gas chromatographic determination of the secondary amine alprenolol and its trifluoroacetyl derivative at nanogram levels in biological fluids. Acta pharm. suec.6, 383 - 400 (1969)
George, C.F., Conolly, M.E., Fenyvesi, T., Briant, R., Dollery, C.T.: Intravenously administered isoproterenol sulfate dose-response curves in man. Arch. int. Med.180, 361 - 364 (1972)
Hansson, L.: Beta-adrenergic blockade in essential hypertension. Acta med. scand. Suppl.550, 1 - 40 (1973)
Johansson, R., Regårdh, C.G., Sjögren, J.: Absorption of alprenolol in man from tablets with different rates of release. Acta pharm. suec.8, 59- 70 (1971)
Johnsson, G. (ed.): The effect of the β-adrenergic blocker alprenolol in hypertension. Acta. med. scand. Suppl.554, 5 – 62 (1974)
Lemberg, L., Arcebal, A.G., Castellanos, A., Slavia, D.: Use of alprenolol in acute cardiac arrhythmias. Amer. J. Cardiol.30, 77- 81 (1972)
Leonetti, G., Mayer, G., Morganti, A., Terzoli, L., Zanchetti, A., Bianchetti, G., DiSalle, E., Morselli, P.L., Chidsey, C.A.: Hypotensive and renin-suppressing activities of propranolol in hypertensive patients. Clin. Sci. mol. Med.48, 491 - 499 (1975)
Paterson, J.W., Conolly, M.E., Dollery, C.T., Hayes, A., Cooper, R.G.: The pharmacodynamics and metabolism of propranolol in man. Pharmacol. Clin.2, 127 - 133 (1970)
Rawlins, M.D., Collste, P., Frisk-Holmberg, M., Lind, M., Östman, J., Sjöqvist, F.: Steady-state concentrations of alprenolol. Europ. J. clin. Pharmacol.7, 353 - 356 (1974)
Shand, D.G., Nuckolls, M.S., Oates, J.A.: Plasma propranolol levels in adults with observations in four children. Clin. Pharmacol. Ther.11, 112 -120 (1970)
Shand, D.G., Rangno, R.E.: The disposition of propranolol. I. Elimination during oral absorption in man. Pharmacol.7, 159 - 168 (1972)
Sowton, E., Smithen, C., Woods, J.: A double-blind three dose trial of oral alprenolol in angina pectoris. Brit. Heart. J.33, 601 - 606 (1971)
Zachest, R., Koch-Weser, J.: Relation of propranolol plasma level to β-blockade during oral therapy. Pharmacol.7, 178 - 184 (1972)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Collste, P., Haglund, K., Frisk-Holmberg, M. et al. Pharmacokinetics and pharmacodynamics of alprenolol in the treatment of hypertension. Eur J Clin Pharmacol 10, 85–88 (1976). https://doi.org/10.1007/BF00609464
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00609464